Abstract

VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects
S Béliard ... J Ferrières
Atherosclerosis | VOL. 234
S Béliard, et. al.S Béliard ... J Ferrières
03 Mar 2014
ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia
B.C.L Carlsson ... L Wernevik
Atherosclerosis | VOL. 355
B.C.L Carlsson, et. al.B.C.L Carlsson ... L Wernevik
01 Aug 2022
Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants
Yukiyo Yamamoto ... Fuyu Miyake
Early Human Development | VOL. 90
Yukiyo Yamamoto, et. al.Yukiyo Yamamoto ... Fuyu Miyake
15 Aug 2014
Prevalence, clinical characteristics and prognosis of intracranial artery atherosclerosis in heterozygous familial hypercholesterolemia: insights from magnetic resonance angiography imaging analysis
M Hori ... T Doi
European Heart Journal | VOL. 41
M Hori, et. al.M Hori ... T Doi
01 Nov 2020
View more papers

More From: European heart journal. Cardiovascular pharmacotherapy

Paper Title
Journal
Date
Author
Re: Shahim et al., 2024 cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
Arina A Tamborska ... Tobias Kurth
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Arina A Tamborska, et. al.Arina A Tamborska ... Tobias Kurth
28 May 2024
Long-term Effects of Phosphodiesterase-5 Inhibitors on Cardiovascular Outcomes and Death: A Systematic Review and Meta-analysis.
Stergios Soulaidopoulos ... Charalambos Vlachopoulos
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Stergios Soulaidopoulos, et. al.Stergios Soulaidopoulos ... Charalambos Vlachopoulos
22 May 2024
Utilizing genetics and proteomics to assess the role of antihypertensive drugs in human longevity and the underlying pathways: a Mendelian randomization study.
Bohan Fan ... Jie V Zhao
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Bohan Fan, et. al.Bohan Fan ... Jie V Zhao
20 May 2024
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension.
Juan Tamargo
European heart journal. Cardiovascular pharmacotherapy | VOL. -
Juan TamargoJuan Tamargo
16 May 2024
View more papers